Filing Flows

Filing Flows › Lineage Cell Therapeutics (LCTX) › Who owns the stock

Who owns Lineage Cell Therapeutics (LCTX) stock

129 funds reported Lineage Cell Therapeutics (LCTX) shares in their latest 13F filings, worth $166M in all. The largest holder is Broadwood Capital ($64.9M). Last quarter 52 funds added to their stakes and 61 cut them.

Largest holders of LCTX (13F)Largest holders of LCTX (13F)Broadwood Capital$64.9MBlackRock$17.3MVanguard Group$16.1MVanguard Capital Management LLC$11.9MGeode Capital Management, LLC$6.9MRaffles Associates LP$6.8MDefender Capital, LLC.$6.4MFifth Third Bancorp$6.0MMillennium Management LLC$4.0MState Street$3.0M

Largest holders (13F)

FundSharesValueChangeQuarter
Broadwood Capital49,560,992$64.9Munchanged2026-06-30
BlackRock13,186,895$17.3Mincrease2026-06-30
Vanguard Group9,644,276$16.1Mincrease2025-12-31
Vanguard Capital Management LLC9,054,918$11.9Mincrease2026-06-30
Geode Capital Management, LLC5,299,457$6.9Mincrease2026-06-30
Raffles Associates LP5,197,788$6.8Mdecrease2026-06-30
Defender Capital, LLC.6,648,899$6.4Mincrease2026-09-30
Fifth Third Bancorp4,600,000$6.0Munchanged2026-06-30
Millennium Management LLC3,018,567$4.0Mdecrease2026-06-30
State Street2,314,180$3.0Mincrease2026-06-30
Vanguard Fiduciary Trust1,668,629$2.2Mincrease2026-06-30
Northern Trust1,656,651$2.2Mincrease2026-06-30
Morgan Stanley1,471,462$1.9Mdecrease2026-06-30
Renaissance Technologies LLC1,344,829$1.8Mdecrease2026-06-30
Marshall Wace, LLP1,282,347$1.7Mdecrease2026-06-30

Lineage Cell Therapeutics' latest quarter

Lineage Cell Therapeutics, Q2 2026: revenue $1.1M (-61% year over year), operating margin -834.7%, net earnings $1.5M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most LCTX stock?

By the latest 13F filings: Broadwood Capital ($64.9M); BlackRock ($17.3M); Vanguard Group ($16.1M); Vanguard Capital Management LLC ($11.9M); Geode Capital Management, LLC ($6.9M).

What is the short interest in LCTX?

25,927,289 shares were sold short at the 2026-10-15 settlement, -10.88% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.